Compare SPRO & INMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SPRO | INMB |
|---|---|---|
| Founded | 2013 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 71.6M | 57.9M |
| IPO Year | 2017 | 2018 |
| Metric | SPRO | INMB |
|---|---|---|
| Price | $1.21 | $2.40 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $5.40 |
| AVG Volume (30 Days) | ★ 607.0K | 358.8K |
| Earning Date | 05-13-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 111.81 | 11.85 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $66,802,000.00 | $50,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $300.00 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 39.24 | ★ 257.14 |
| 52 Week Low | $1.08 | $1.09 |
| 52 Week High | $3.08 | $2.50 |
| Indicator | SPRO | INMB |
|---|---|---|
| Relative Strength Index (RSI) | 34.07 | 70.66 |
| Support Level | $1.18 | $1.16 |
| Resistance Level | $1.29 | N/A |
| Average True Range (ATR) | 0.05 | 0.12 |
| MACD | 0.03 | 0.03 |
| Stochastic Oscillator | 16.00 | 83.84 |
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
INmune Bio Inc is a clinical stage biotechnology pharmaceutical company focused on developing and commercializing its product candidates to treat diseases where inflammation and immunology cause a dysfunctional immune system contributing to disease. The company's pipeline products include INKmune, XPro1595, and others. It has three product platforms; The CORDStrom product platform, The DN-TNF product platform, and The Natural Killer Cell Priming Platform.